Thomas Müller

8.7k total citations · 3 hit papers
55 papers, 4.2k citations indexed

About

Thomas Müller is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Thomas Müller has authored 55 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in Thomas Müller's work include CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (15 papers) and Lung Cancer Treatments and Mutations (8 papers). Thomas Müller is often cited by papers focused on CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (15 papers) and Lung Cancer Treatments and Mutations (8 papers). Thomas Müller collaborates with scholars based in Germany, United States and Austria. Thomas Müller's co-authors include Christian Manegold, Miklos Pless, Sofia Paul, Joachim von Pawel, Paolo Paoletti, Frances A. Shepherd, Filippo de Marinis, Thomas Chang Yao Tsao, U. Gatzemeier and Shaharyar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Thomas Müller

54 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Thomas Müller, Christian Manegold et al. profile →
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Thomas Müller et al. profile →
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

2015 340 citations Thomas Müller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Müller Germany	23	2.5k	2.2k	949	726	409	55	4.2k
Jennifer Gansert United States	16	3.7k 1.5×	1.2k 0.5×	876 0.9×	911 1.3×	492 1.2×	31	4.5k
William N. William United States	33	2.0k 0.8×	1.5k 0.7×	893 0.9×	371 0.5×	559 1.4×	109	4.0k
Jun Gong United States	28	2.1k 0.8×	843 0.4×	924 1.0×	660 0.9×	569 1.4×	163	3.4k
Arun Rajan United States	34	1.7k 0.7×	889 0.4×	1.0k 1.1×	419 0.6×	302 0.7×	136	3.8k
Kazuhiko Yamada Japan	25	1.4k 0.6×	952 0.4×	573 0.6×	307 0.4×	321 0.8×	121	2.6k
Massimo Barberis Italy	38	1.9k 0.8×	1.5k 0.7×	849 0.9×	352 0.5×	884 2.2×	204	4.2k
William J. John United States	29	3.0k 1.2×	2.9k 1.3×	972 1.0×	384 0.5×	585 1.4×	84	4.5k
Yuankai Shi China	36	3.5k 1.4×	2.9k 1.3×	1.8k 1.9×	572 0.8×	1.0k 2.5×	312	6.0k
Kiyotaka Yoh Japan	35	3.0k 1.2×	2.6k 1.2×	1.4k 1.4×	179 0.2×	740 1.8×	271	4.6k
Anna Spreafico Canada	31	2.3k 0.9×	1.2k 0.5×	1.2k 1.3×	567 0.8×	591 1.4×	229	3.8k

Countries citing papers authored by Thomas Müller

Since Specialization

Citations

This map shows the geographic impact of Thomas Müller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Müller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Müller more than expected).

Fields of papers citing papers by Thomas Müller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Müller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Müller. The network helps show where Thomas Müller may publish in the future.

Co-authorship network of co-authors of Thomas Müller

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Müller. A scholar is included among the top collaborators of Thomas Müller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Müller. Thomas Müller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boulouis, Caroline, Thomas Müller, Jeffrey Y. W. Mak, et al.. (2025). Human MAIT cell response profiles biased toward IL-17 or IL-10 are distinct effector states directed by the cytokine milieu. Proceedings of the National Academy of Sciences. 122(6). e2414230122–e2414230122. 8 indexed citations

Müller, Thomas, Takuya Sekine, Julia Niessl, et al.. (2023). Anamnestic expansion of Omicron-reactive CD8+ T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states. The Journal of Immunology. 210(Supplement_1). 75.16–75.16. 1 indexed citations

Müller, Thomas & Marcus Buggert. (2023). Boosting SARS-CoV-2 immunity in immunocompromised individuals. Genes and Immunity. 25(2). 168–169. 2 indexed citations

Müller, Thomas, Sebastian Jarosch, Justin Leube, et al.. (2021). Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Reports Medicine. 2(8). 100374–100374. 36 indexed citations

Müller, Thomas, Sabrina Jutz, Judith Leitner, et al.. (2020). A T‐cell reporter platform for high‐throughput and reliable investigation of TCR function and biology. Clinical & Translational Immunology. 9(11). e1216–e1216. 17 indexed citations

Schober, Kilian, Thomas Müller, & Dirk H. Busch. (2020). Orthotopic T-Cell Receptor Replacement—An “Enabler” for TCR-Based Therapies. Cells. 9(6). 1367–1367. 14 indexed citations

Schober, Kilian, Thomas Müller, Simon Grassmann, et al.. (2019). Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nature Biomedical Engineering. 3(12). 974–984. 115 indexed citations

Effenberger, Manuel, Andreas Stengl, Kilian Schober, et al.. (2019). FLEXamers: A Double Tag for Universal Generation of Versatile Peptide-MHC Multimers. The Journal of Immunology. 202(7). 2164–2171. 13 indexed citations

Leonhardt, Franziska, Christian Stemberger, Stefan Dreher, et al.. (2018). Efficient immunoaffinity chromatography of lymphocytes directly from whole blood. Scientific Reports. 8(1). 16731–16731. 11 indexed citations

10.

Gantke, Thorsten, Uwe Reusch, Christian Kellner, et al.. (2017). AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma. Blood. 130. 3082–3082. 6 indexed citations

11.

Gantke, Thorsten, Michael Weichel, Uwe Reusch, et al.. (2017). Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering Design and Selection. 30(9). 673–684. 46 indexed citations

12.

Späth, Christoph, Ulrich Nitsche, Thomas Müller, et al.. (2015). Strategies to improve the outcome in locally advanced pancreatic cancer.. mediaTUM (Technical University of Munich). 70(2). 97–106. 7 indexed citations

13.

Schuette, Wolfgang, A Gröschel, Martin Sebastian, et al.. (2013). A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(3). 215–223. 39 indexed citations

14.

Molen, Thys van der, Juliet M. Foster, Manfred Caeser, Thomas Müller, & Dirkje S. Postma. (2010). Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. Respiratory Medicine. 104(12). 1825–1833. 8 indexed citations

15.

Bauer, Stefan, Thomas Müller, & Svetlana Hamm. (2009). Pattern Recognition by Toll-like Receptors. Advances in experimental medicine and biology. 653. 15–34. 70 indexed citations

16.

Kalali, Behnam, Gabriele Köllisch, Jörg Mages, et al.. (2008). Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling. The Journal of Immunology. 181(4). 2694–2704. 147 indexed citations

17.

Boulet, Louis‐Philippe, et al.. (2007). A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respiratory Medicine. 101(8). 1677–1686. 43 indexed citations

18.

Gridelli, Cesare, E. Kaukel, Vanesa Gregorc, et al.. (2007). Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial. Journal of Thoracic Oncology. 2(3). 221–229. 35 indexed citations

19.

Laack, Eckart, Thorsten Mende, A. Chemaissani, et al.. (2001). Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer. European Journal of Cancer. 37(5). 583–590. 27 indexed citations

20.

Arbeiter, Klaus, Laurence Greenbaum, E Balzar, et al.. (2000). Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatric Nephrology. 14(3). 195–197. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact